The administration of sequential treatments of cisplatin and PI3K/AKT inhibitor could improve the poor efficacy, supporting the case that sequential treatment including PI3K/AKT inhibitor could be adopted for various anti-cancer strategies [28]. The gene discussed is AKT1; the disease is cancer.